Core - Biomarker Development Laboratory (BDL)

核心 - 生物标志物开发实验室 (BDL)

• 批准号: 10705802
• 负责人: JAMES G. HERMAN
• 金额: $ 38.24万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-16 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10705802
• 关键词: Anatomy; Apoptotic; Benign; Biological; Biological Markers; Blood; Body Fluids; Breast; Cancer Detection; Cancer Etiology; Categories; Classification; Clinical; Collection; Colorectal; DNA; DNA Methylation; Data; Detection; Development; Diagnosis; Diagnostic; Diagnostic Procedure; Diameter; Early Detection Research Network; Early Diagnosis; Epigenetic Process; Event; Funding; Genetic; Head and neck structure; Healthcare; High Prevalence; Histology; Laboratories; Location; Low Prevalence; Lung; Lung nodule; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of lung; Measures; Methods; Methylation; Molecular; Monitor; Necrosis; Nodule; Nucleic Acids; Pancreas; Participant; Patients; Performance; Plasma; Process; Prostate; Reporting; Research Design; Research Personnel; Sampling; Screening for cancer; Sensitivity and Specificity; Source; Specimen; Standardization; Testing; The Cancer Genome Atlas; Tissues; United States; Validation; biomarker development; bisulfite; cancer biomarkers; cancer type; circulating DNA; clinical implementation; computed tomography screening; cost effective; design; detection assay; detection method; digital; improved; laboratory development; low dose computed tomography; lung cancer screening; methylation biomarker; mortality; multidisciplinary; neoplastic cell; novel; performance tests; prospective; screening; tumor; tumor DNA; tumorigenesis; wasting

As part of a Biomarker Characterization Center, the Biomarker Development Laboratory will develop improved methods to detect DNA methylation changes for the early detection of lung cancer. Led by Dr. James Herman and Dr. Tza-Huei Jeff Wang, a multidisciplinary team of investigators will develop improved panels of DNA methylation alterations able to detect circulating tumor DNA (ctDNA) changes in plasma, to determine the origin of ctDNA from lung cancer or other common malignancies, and to continue improvements in methylation detection methods to better detect the small amounts of ctDNA present in plasma. This EDRN Biomarker Development Laboratory will use high quality, prospectively collected biospecimens to develop highly sensitive, specific and quantitative approaches for the detection of tumor-specific DNA methylation abnormalities in plasma. These methods will be transferred to the Biomarker Reference Laboratory to be standardized and tested for performance in a CLIA setting.

作为生物标志物表征中心的一部分，生物标志物开发实验室 将开发改进的方法来检测DNA甲基化变化，以便早期发现 肺癌。由 James Herman 博士和 Tza-Huei Jeff Wang 博士领导的多学科团队 研究小组将开发改进的 DNA 甲基化改变组，能够 检测血浆中循环肿瘤 DNA (ctDNA) 的变化，以确定肿瘤的来源 来自肺癌或其他常见恶性肿瘤的 ctDNA，并持续改进 甲基化检测方法，以更好地检测存在于其中的少量 ctDNA 等离子体。该 EDRN 生物标志物开发实验室将使用高质量、 前瞻性收集的生物样本，以开发高度敏感、特异和 检测肿瘤特异性 DNA 甲基化的定量方法 血浆异常。这些方法将转移到生物标记参考 实验室将在 CLIA 环境中进行标准化和性能测试。